Prospect: information for the user
Septanest with adrenaline40mg/ml + 5micrograms/ml injectable solution
Septanest with adrenaline40mg/ml + 10micrograms/ml injectable solution
articaína hydrochloride/epinephrine
Read this prospect carefully before starting to use this medication, as it contains important information for you.
1.What isSeptanest withadrenalineand for what it is used
2.What you need to know before being administeredSeptanest withadrenaline
3.How to useSeptanest withadrenaline
4.Possible adverse effects
5.Storage ofSeptanest withadrenaline
6.Contents of the package and additional information
Septanest withadrenalineis used to numb (anesthetize) the oral cavity during dental procedures.
This medication contains two active principles:
Your dentist will administer Septanest with adrenaline 40 mg/ml + 5 micrograms/ml or Septanest with adrenaline 40 mg/ml + 10 micrograms/ml.
Septanest withadrenaline is indicated for children over 4years (approximately 20kg of body weight), adolescents, and adults.
Depending on the type of dental procedure performed, the dentist will choose one of the two medications:
No useSeptanest with adrenaline if you have any of the following medical conditions:
Warnings and precautions
Consult your dentist before starting to useSeptanest withadrenalineif you have any of the following medical conditions:
Use ofSeptanest withadrenalinewith other medications
Inform your dentist if you are taking, have taken recently, or may need to take any other medication.
It is extremely important to inform your dentist if you are taking any of the following medications:
Use ofSeptanest withadrenalinewith food
Avoid eating, even chewing gum, until you have recovered normal sensation. Otherwise, there is a risk of biting your lips, cheeks, or tongue, especially in children.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your dentist or doctor before using this medication.
Your dentist or doctor will decide if you can takeSeptanest withadrenalineduring pregnancy.
Breastfeeding can be resumed 5hours after anesthesia.
No adverse effects on fertility are expected with the doses used in dental procedures.
Driving and operating machinery
If you experience adverse effects, including dizziness, blurred vision, or fatigue, do not drive or operate machinery until you have recovered your faculties (usually within 30minutes after the dental procedure).
Septanest withadrenalinecontains sodium and sodium metabisulfite.
If there is any risk of an allergic reaction, your dentist will choose another medication for anesthesia.
Only doctors and dentists are trained to useSeptanest withadrenaline.
Your dentist will choose between Septanest with adrenaline 40 mg/ml + 5 micrograms/ml or Septanest with adrenaline 40 mg/ml + 10 micrograms/ml and will determine the appropriate dose taking into account your age, weight, general health status and dental procedure.
The lowest dose that provides effective anesthesia should be used.
This medication is administered via a slow injection into the oral cavity.
If you use moreSeptanest withadrenaline than you should
It is unlikely that you will be administered too much of this injection, but if you start to feel unwell, tell your dentist. Symptoms of overdose include acute weakness, pale skin, headache, agitation or restlessness, disorientation, loss of balance, involuntary tremors or shakiness, dilated pupils, blurred vision, difficulty focusing on objects clearly, speech alterations, dizziness, convulsions, stupor, loss of consciousness, coma, yawning, abnormally slow or rapid breathing that may lead to temporary respiratory arrest, inability of the heart to contract (cardiac failure).
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 915 620 420, indicating the medication and the amount ingested.
If you have any other questions about the use of this medication, ask your dentist.
Like all medicines, this medicine may cause side effects, although not everyone will experience them.
When you are at the dentist's office, the dentist will closely monitor the effects ofSeptanest withadrenaline.
Inform your dentist, doctor or pharmacistimmediatelyif you experience any of the following severe side effects:
These side effects are rare (they may affect up to 1 in 1,000people).
In other patients, other side effects not listed above may also appear.
Frequent side effects: they may affect up to 1 in 10people:
Less frequent side effects: they may affect up to 1 in 100people:
Rare side effects: they may affect up to 1 in 1,000people:
Very rare side effects: they may affect up to 1 in 10,000people:
Frequency not known: cannot be estimated from available data
Reporting of side effects
If you experience any type of side effect, consult your dentist, doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through theSistema Español de Farmacovigilancia de Medicamentos de Uso Humano:www.notificaRAM.es.
By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the label and the box after CAD. The expiration date is the last day of the month indicated.
Store below 30°C.
Do not freeze.
Store the cartridges in the outer packaging to protect them from light.
Do not use this medication if you see that the solution is cloudy or has changed color.
The cartridges are for single use. Use immediately after opening the cartridge. Unused solution should be discarded.
Medications should not be thrown down the drain or in the trash. Your dentist will know how to dispose of the medications that you no longer use. In this way, you will help protect the environment.
Composition ofSeptanest withadrenaline
Appearance of the product and contents of the package
Septanest with adrenaline is a transparent and colorless solution.
It is packaged in single-use glass cartridges, sealed at the base with a movable rubber plunger and at the top with a rubber seal held by an aluminum cap.
Box containing 50 glass cartridges of 1.7 ml.
Box containing 50 auto-aspirable glass cartridges of 1.7 ml.
Package containing 4 boxes of 50 glass cartridges of 1.7 ml.
Package containing 8 boxes of 50 glass cartridges of 1.7 ml.
Only certain package sizes may be marketed.
Marketing authorization holder and responsible manufacturer
Septodont
58, rue du Pont de Créteil
94100 Saint-Maur-des-Fossés
France
This medicinal product is authorized in the member states of the European Economic Area with the following names:
Austria:Septanest mit Epinephrin 1:200.000 - 40 mg/ml + 5 Mikrogramm/ml, Injektionslösung
Septanest mit Epinephrin 1:100.000 - 40 mg/ml + 10 Mikrogramm/ml, Injektionslösung
Bulgaria:???????????????????1/200 000,40mg/ml+5??????????/ml??????????????????
???????????????????1/100 000,40mg/ml+10??????????/ml??????????????????
Croatia:Septanest 40 mg/ml + 0.005 mg/ml otopina za injekciju
Septanest Forte 40 mg/ml + 0.01 mg/ml otopina za injekciju
Cyprus:Septanest, 40 mg/ml + 5 micrograms/ml, εν?σιμο δι?λυμα
Septanest Forte, 40 mg/ml + 10 micrograms/ml, εν?σιμο δι?λυμα
Czech Republic:Septanest s adrenalinem 1:200 000, 40 mg/ml + 5 mikrogramu/ml, injekcní roztok
Septanest s adrenalinem 1:100 000, 40 mg/ml + 10 mikrogramu/ml, injekcní roztok
Denmark:Septanest, 40 mg/ml + 5 mikrogram/ml, injektionsvæske, opløsning
Septocaine, 40 mg/ml + 10 mikrogram/ml, injektionsvæske, opløsning
Estonia:Septanest, 40 mg/ml + 5 mikrogrammi/ml, süstelahus
Septanest Forte, 40 mg/ml + 10 mikrogrammi/ml, süstelahus
Finland:Septocaine, 40 mg/ml + 5 mikrogrammaa/ml, injektioneste, liuos
Septocaine Forte, 40 mg/ml + 10 mikrogrammaa/ml, injektioneste, liuos
France:Septanest 40 mg/mL Adrénalinée au 1/200 000, solution injectable à usage dentaire
Septanest 40 mg/mL Adrénalinée au 1/100 000, solution injectable à usage dentaire
Germany:Septanest mit Epinephrin 1:200.000 - 40 mg/ml + 0.005 mg/ml Injektionslösung
Septanest mit Epinephrin 1:100.000 - 40 mg/ml + 0.01 mg/ml Injektionslösung
Greece:Septanest 4% + 1:200.000, εν?σιμο δι?λυμα
Septanest 4% + 1:100.000, εν?σιμο δι?λυμα
Hungary:Septanest 40 mg/ml + 10 mikrogramm/ml, injekciós oldat
Italy:Septanest 40 mg/ml + 5 microgrammi/ml soluzione iniettabile con adrenalina
Septanest 40 mg/ml + 10 microgrammi/ml soluzione iniettabile con adrenalina
Latvia:Septanest 40 mg/ml + 5 mikrogrami/ml škidums injekcijam
Septanest Forte 40 mg/ml + 10 mikrogrami/ml škidums injekcijam
Lithuania:Septanest 40 mg/ml + 5 mikrogramai/ml, injekcinis tirpalas
Septanest Forte 40 mg/ml + 10 mikrogramai/ml, injekcinis tirpalas
Luxembourg:Septanest Normal, 40 mg/ml+ 5 microgrammes/ml, solution injectable
Septanest Spécial, 40 mg/ml+ 10 microgrammes/ml, solution injectable
Malta:Septanest with adrenaline 1/200,000, 40 mg/ml + 5 micrograms/ml solution for injection
Septanest with adrenaline 1/100,000, 40 mg/ml + 10 micrograms/ml, solution for injection
Netherlands:Septanest N 40 mg/ml + 5 microgram/ml, oplossing voor injectie
Septanest SP 40 mg/ml + 10 microgram/ml, oplossing voor injectie
Norway:Septocaine 40 mg/ml+5 mikrogram/ml, injeksjonsvæske, oppløsning
Septocaine Forte 40 mg/ml+10 mikrogram/ml, injeksjonsvæske, oppløsning
Poland:SEPTANEST Z ADRENALINA 1: 200 000 (40 mg+0.005mg)/ml, roztwór do wstrzykiwan
SEPTANEST Z ADRENALINA 1: 100 000 (40 mg+0.01mg)/ml, roztwór do wstrzykiwan
Portugal:Septanest 1/200,000, 40 mg/ml + 5 microgramas/ml, solução injetável
Septanest 1/100,000, 40 mg/ml + 10 microgramas/ml, solução injetável
Romania:SEPTANEST CU ADRENALINA 1/200000 40 mg/0.005 mg/ml solutie injectabila
SEPTANEST CU ADRENALINA 1/100000 40 mg/0.01 mg/ml solutie injectabila
Slovakia:Septanest 40 mg/ml + 5 mikrogramov/ml injekcný roztok
Septanest Forte 40 mg/ml + 10 mikrogramov/ml injekcný roztok
Slovenia:Septanestepi 40 mg/0.005 mg v 1 ml raztopina za injiciranje
Septanestepi 40 mg/0.01 mg v 1 ml raztopina za injiciranje
Spain:Septanest con adrenalina 40 mg/ml + 5 microgramos/ml solución inyectable
Septanest con adrenalina 40 mg/ml + 10 microgramos/ml solución inyectable
Sweden:Septocaine 40 mg/ml + 5 mikrogram/ml, injektionsvätska, lösning
Septocaine Forte 40 mg/ml + 10 mikrogram/ml, injektionsvätska, lösning
Last review date of this leaflet:
05/2022
Other sources of information
The detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/.
--------------------------------------------------------------------------------------------------------------------------------------
This information is intended solely for healthcare professionals:
Posology
For all populations, the lowest effective dose should be used. The required dose should be determined on an individual basis.
For routine procedures, the normal dose for adult patients is 1 cartridge, but the contents of less than one cartridge may be sufficient for effective anesthesia. According to the dentist's judgment, more cartridges may be required for more extensive procedures, without exceeding the recommended maximum dose.
For most routine dental procedures, Septanest with adrenaline 40 mg/ml + 5 micrograms/ml is preferred.
For more complex procedures, such as pronounced hemostasis, Septanest with adrenaline 40 mg/ml + 10 micrograms/ml solution is preferred.
Concomitant use of sedatives to reduce patient anxiety:
The maximum safe dose of local anesthetic may be reduced in sedated patients due to an additive effect on central nervous system depression.
Adults and adolescents (12 to 18 years old)
In adults and adolescents, the maximum dose of articaine is 7 mg/kg, with a maximum absolute dose of articaine of 500 mg. The maximum dose of articaine of 500 mg corresponds to a healthy adult of more than 70 kg body weight.
Children (4 to 11 years old)
No safety data are available for children 4 years and younger. No data are available.
The amount to be injected should be determined by the child's age and weight and the magnitude of the operation. The average effective dose is 2 mg/kg and 4 mg/kg for simple and complex procedures, respectively. The lowest dose that provides effective dental anesthesia should be used.
In children 4 years (or 20 kg (44 lbs) body weight) and older, the maximum dose of articaine is only 7 mg/kg, with a maximum absolute dose of 385 mg of articaine for a healthy child of 55 kg body weight.
Special populations
Older adults and patients with renal impairment:
Due to the lack of clinical data, special precautions should be taken to administer the lowest effective dose in older adults and patients with renal impairment.
Prolonged high plasma levels of the drug may occur in these patients, especially after repeated use. In case of requiring re-injection, the patient should be closely monitored to identify any signs of relative overdose.
Patients with hepatic impairment
For patients with hepatic impairment, special precautions should be taken to administer the lowest effective dose, especially after repeated use, although 90% of articaine is first inactivated by non-specific tissue and blood esterases.
Patients with plasma cholinesterase deficiency
Prolonged high plasma levels of the drug may occur in patients with plasma cholinesterase deficiency or under treatment with cholinesterase inhibitors, as the product is inactivated in 90% by plasma esterases. Therefore, the lowest dose that provides effective anesthesia should be used.
Administration
Infiltration and perineural injection in the oral cavity.
If there is inflammation and/or infection at the injection site, local anesthesia should be injected with caution. The injection rate should be very slow (1 ml/min).
Precautions to be taken before handling or administering the drug
This drug should only be used by a doctor or dentist with sufficient training and familiar with the diagnosis and treatment of systemic toxicity, or under their supervision. Before inducing regional anesthesia with local anesthetics, it should be ensured that a resuscitation team and appropriate medication are available for immediate treatment of any respiratory or cardiovascular emergency. The patient's level of consciousness should be monitored after each injection of local anesthesia.
When using Septanest with adrenaline for infiltration or regional anesthetic block, the injection should always be administered slowly and with prior aspiration.
Special warnings
Adrenaline reduces blood flow to the gums, which may cause local tissue necrosis.
Rare cases of prolonged or irreversible nerve damage and taste loss have been reported after mandibular block analgesia.
Precautions for use
Risk associated with accidental intravascular injection:
An accidental intravascular injection may cause high levels of adrenaline and articaine in the systemic circulation.This may be associated with severe adverse reactions, such as convulsions, followed by central nervous system and cardiovascular depression, and coma, which may progress to respiratory and circulatory arrest.
To ensure that the needle does not penetrate a blood vessel during injection, aspiration should be performed before injecting the local anesthetic. However, the absence of blood in the syringe does not guarantee that an intravascular injection has not occurred.
Risk associated with accidental intraneural injection:
An accidental intraneural injection may cause the drug to move retrogradely along the nerve.
To avoid intraneural injection and prevent nerve damage when performing nerve blocks, the needle should be withdrawn slightly whenever the patient feels a sensation of discharge during injection or if the injection is particularly painful. If nerve damage occurs due to the needle, the chemical neurotoxicity of articaine and the presence of adrenaline may exacerbate the effect, as adrenaline may reduce perineural blood flow and prevent local elimination of articaine.
Treatment of overdose
Before administering regional anesthesia with local anesthetics, it should be ensured that a resuscitation team and appropriate medication are available for immediate treatment of any respiratory or cardiovascular emergency.
According to the severity of the symptoms of overdose, the doctor or dentist should implement protocols that anticipate the need to protect airways and provide assisted ventilation
The patient's level of consciousness should be monitored after each injection of local anesthesia.
If signs of acute systemic toxicity occur, the injection of local anesthetic should be stopped immediately. If necessary, place the patient in a supine position.
CNS symptoms (convulsions, CNS depression) should be treated immediately with appropriate respiratory support and administration of anticonvulsants.
Optimal oxygenation and ventilation, along with circulatory support and treatment of acidosis, may prevent cardiac arrest.
If cardiovascular depression (hypotension, bradycardia) occurs, appropriate treatment with intravenous fluids, vasopressors, or inotropic agents should be considered. Children should receive doses appropriate to their age and weight.
In case of cardiac arrest, immediate cardiopulmonary resuscitation should be performed.
Special precautions for disposal and other handling
This drug should not be used if the solution is turbid or has changed color.
To avoid the risk of infection (e.g., transmission of hepatitis), the syringe and needles used to prepare the solution should always be new and sterile.
The cartridges are for single use only. If only part of the cartridge is used, the rest should be discarded.
The disposal of unused medication and all materials that have come into contact with it should be carried out in accordance with local regulations.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.